Processing

Please wait...

Settings

Settings

1. WO2000042178 - ANTAGONIST BLOCKADE OF CRF¿2? RECEPTORS FOR THE TREATMENT OF PSY CHIATRIC DISORDERS AND THE USE OF CHIMERIC ANTISENSE OLIGONUCLEOTIDES IN IN VIVO CNS STUDIES OF GENE FUNCTION

Publication Number WO/2000/042178
Publication Date 20.07.2000
International Application No. PCT/US2000/000819
International Filing Date 13.01.2000
Chapter 2 Demand Filed 27.07.2000
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C12N 15/11 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C12N 15/1138
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
1138against receptors or cell surface proteins
C12N 2310/315
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
31of the backbone
315Phosphorothioates
C12N 2310/321
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
32of the sugar
3212'-O-R Modification
C12N 2310/346
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2310Structure or type of the nucleic acid
30Chemical structure
34Spatial arrangement of the modifications
346having a combination of backbone and sugar modifications
Applicants
  • DUPONT PHARMACEUTICALS COMPANY [US/US]; Chestnut Run Plaza 974 Centre Road Wilmington, DE 19805, US
Inventors
  • HO, Siew, Peng; US
Agents
  • WILK-ORESCAN, Rosemarie, R.; Dupont Pharmaceuticals Company Legal Patent Records Center 1007 Market Street Wilmington, DE 19898, US
Priority Data
60/115,74813.01.1999US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTAGONIST BLOCKADE OF CRF2 RECEPTORS FOR THE TREATMENT OF PSY CHIATRIC DISORDERS AND THE USE OF CHIMERIC ANTISENSE OLIGONUCLEOTIDES IN IN VIVO CNS STUDIES OF GENE FUNCTION
(FR) BLOCAGE DES RECEPTEURS DE TYPE 2 DE LA CORTICOLIBERINE PAR DES ANTAGONISTES DANS LE TRAITEMENT DES TROUBLES PSYCHIATRIQUES ET UTILISATION D'OLIGONUCLEOTIDES CHIMERES ANTISENS DANS LES ETUDES IN VIVO DE LA FONCTION GENIQUE AU NIVEAU DU SYSTEME NERVEUX CENTRAL
Abstract
(EN)
This invention relates to antisense oligonucleotides directed against the mRNA of the corticotropin releasing factor subtype-2 (CRF2) receptor which substantially reduce expression of CRF2 receptors in the rodent brain and the use of antisense oligonucleotides in $i(in vivo) CNS studies of gene function and to treat a wide range of psychiatric disorders including anxiety, obsessive-compulsive disorder, panic disorders, post-traumatic stress disorder, phobias and depression.
(FR)
La présente invention se rapporte à des oligonucléotides antisens dirigés contre l'ARNm du récepteur de sous-type 2 de la corticolibérine (CRF2) qui réduisent sensiblement l'expression des CRF2 dans le cerveau des rongeurs, et à l'utilisation d'oligonucléotides antisens dans les études $i(in vivo) de la fonction génique au niveau du système nerveux central. L'invention permet de traiter une vaste palette de troubles psychiatriques, y compris l'anxiété, les névroses obsessionnelles, les troubles paniques, les syndromes de stress post-traumatique, les phobies et la dépression.
Also published as
Latest bibliographic data on file with the International Bureau